According to the publication, which cites its own sources in the company, blood tests for immunogenicity, carried out on a subgroup of elderly participants, were similar to those taken from healthy adults aged 18 to 55 years.
It has previously been reported that the vaccine generates "robust immune responses" in this population. In the near future, the company intends to publish data on the results of tests among the elderly.
The vaccine from AstraZeneca and Oxford University is considered one of the most promising on the market. The company and the university have already entered into numerous agreements with the authorities in different countries to supply the vaccine as soon as it passes clinical trials.
At the same time, the FT notes that the development of stable immunity does not mean that the vaccine will be automatically approved. For approval, it also requires the absence of serious side effects.
source: ft.com
It has previously been reported that the vaccine generates "robust immune responses" in this population. In the near future, the company intends to publish data on the results of tests among the elderly.
The vaccine from AstraZeneca and Oxford University is considered one of the most promising on the market. The company and the university have already entered into numerous agreements with the authorities in different countries to supply the vaccine as soon as it passes clinical trials.
At the same time, the FT notes that the development of stable immunity does not mean that the vaccine will be automatically approved. For approval, it also requires the absence of serious side effects.
source: ft.com